TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Training in Pregnancy. Good for the Mother - Good for the Child?
Brief Summary: Observational studies demonstrate that overweight in pregnancy is a risk factor for adverse pregnancy outcomes as fetal macrosomia, prolonged labor, low Apgar score, shoulder dystocia, nerve plexus injuries, increased proportion of instrumental deliveries and perineal ruptures. There is a 2.6 fold risk for gestational diabetes mellitus (fourfold in morbidly obese women) and a recent study has shown that fetuses of obese mothers develop insulin resistance in uterus.

Main aims of this study are to assess if regular exercise in pregnancy among obese women can prevent or influence weight gain; impaired cardiac function in mother and fetus/newborn; impaired vascular function in mother; insulin resistance/sensitivity; body composition in mother and offspring; lumbopelvic pain; urinary and/or fecal incontinence; prolonged labor


Options:
A: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
B: Arm Label: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Other: Yoga Therapy Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Yoga Therapy Program; Assigned to Arm(s): Yoga Therapy
C: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program
D: Intervention Type: BEHAVIORAL; Name: Self-management; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exercise Training in Pregnancy. Good for the Mother - Good for the Child?
Brief Summary: Observational studies demonstrate that overweight in pregnancy is a risk factor for adverse pregnancy outcomes as fetal macrosomia, prolonged labor, low Apgar score, shoulder dystocia, nerve plexus injuries, increased proportion of instrumental deliveries and perineal ruptures. There is a 2.6 fold risk for gestational diabetes mellitus (fourfold in morbidly obese women) and a recent study has shown that fetuses of obese mothers develop insulin resistance in uterus.

Main aims of this study are to assess if regular exercise in pregnancy among obese women can prevent or influence weight gain; impaired cardiac function in mother and fetus/newborn; impaired vascular function in mother; insulin resistance/sensitivity; body composition in mother and offspring; lumbopelvic pain; urinary and/or fecal incontinence; prolonged labor


Options:
A: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
B: Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Other: Lifestyle intervention, Behavioral: Physical activity, dietetic counselling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Other: Control | Intervention Type: OTHER; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Physical activity, dietetic counselling; Assigned to Arm(s): Lifestyle intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low glycemic load | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Low glycemic load; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): 2
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Dental Treatment on Children's Growth
Brief Summary: Severe dental decay affects children physically, emotionally, socially and thereby impacts on their quality of life. Evidence from developed countries showed that children with severe dental decay weighed less than their peers and following dental treatment children's growth and quality of life improved. This suggests that treatment of severe dental decay may enhance growth and wellbeing. A study was carried out in Saudi to test that hypothesis.


Options:
A: Arm Label: I, Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: II, Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): I, Intervention
B: Arm Label: Loss-framed messages; Type: EXPERIMENTAL; Interventions: Behavioral: Framing (Loss-framed messages) | Arm Label: gain-framed messages; Type: EXPERIMENTAL; Interventions: Behavioral: Framing (Gain-framed messages) | Intervention Type: BEHAVIORAL; Name: Framing (Gain-framed messages); Assigned to Arm(s): gain-framed messages | Intervention Type: BEHAVIORAL; Name: Framing (Loss-framed messages); Assigned to Arm(s): Loss-framed messages
C: Intervention Type: BEHAVIORAL; Name: Nutritional and life style counseling; Assigned to Arm(s): N/A
D: Arm Label: Early treatment; Type: EXPERIMENTAL; Interventions: Other: comprehensive dental treatment | Arm Label: Regualr treatment; Type: NO_INTERVENTION; Interventions: Other: Only emergency dental treatment | Intervention Type: OTHER; Name: comprehensive dental treatment; Assigned to Arm(s): Early treatment | Intervention Type: OTHER; Name: Only emergency dental treatment; Assigned to Arm(s): Regualr treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study
Brief Summary: The investigators hypothesized that the early treatment of PDA with ibuprofen doses higher than those actually recommended might increase the closure rate in preterm infants with gestational age \<29 weeks without increasing the occurrence of associated adverse effects. To assess this hypothesis the investigators planned a multicenter randomized controlled study to compare the effectiveness of the current ibuprofen regimen to that of a high-dose regimen in closing PDA.


Options:
A: Arm Label: Small ductus; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Large ductus ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Large ductus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Large ductus ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Large ductus placebo
B: Arm Label: Infant treated with high dose ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Infant treated with high dose ibuprofen
C: Arm Label: ibuprofen group; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: paracetamol group; Type: EXPERIMENTAL; Interventions: Drug: paracetamol | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen group | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol group
D: Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous ibuprofen | Arm Label: O; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral ibuprofen | Intervention Type: DRUG; Name: oral ibuprofen; Assigned to Arm(s): O | Intervention Type: DRUG; Name: intravenous ibuprofen; Assigned to Arm(s): I

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Champix; Type: EXPERIMENTAL; Interventions: Drug: Champix | Arm Label: Long & Combination patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch combined with gum or inhaler | Arm Label: Standard patch treatment; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicoderm patch | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Champix | Intervention Type: DRUG; Name: Transdermal Nicoderm patch combined with gum or inhaler; Assigned to Arm(s): Long & Combination patch treatment | Intervention Type: DRUG; Name: Transdermal Nicoderm patch; Assigned to Arm(s): Standard patch treatment
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Combination zonisamide and bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Zonisamide, Other: E-cigarette | Arm Label: Bupropion with e-cigarette; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Arm Label: Placebo with e-cigarette; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo bupropion, Drug: Placebo zonisamide, Other: E-cigarette | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Combination zonisamide and bupropion with e-cigarette | Intervention Type: DRUG; Name: Placebo bupropion; Assigned to Arm(s): Placebo with e-cigarette | Intervention Type: DRUG; Name: Placebo zonisamide; Assigned to Arm(s): Bupropion with e-cigarette, Placebo with e-cigarette | Intervention Type: OTHER; Name: E-cigarette; Assigned to Arm(s): Bupropion with e-cigarette, Combination zonisamide and bupropion with e-cigarette, Placebo with e-cigarette
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
B: Arm Label: study groups; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): study groups | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): control group
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: EVT 302 plus open label Nicotine replacement | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo plus open label Nicotine Replacement | Intervention Type: DRUG; Name: EVT 302; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: EVT 302 plus open label Nicotine replacement; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo plus open label Nicotine Replacement; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: SAMe 800; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: SAMe 1600; Type: ACTIVE_COMPARATOR; Interventions: Drug: S-Adenosyl-L-Methionine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 800 | Intervention Type: DRUG; Name: S-Adenosyl-L-Methionine; Assigned to Arm(s): SAMe 1600 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D